Although the inclusion of more than one center may better resemble the clinical setting and enable a validation strategy, separate analyses of the two cohorts rendered too small subgroups for some statistical analyses, where more cases would have been needed to fully evaluate the prognostic value of RBM3 in, for example, different lung cancer stages and in relation to adjuvant treatment. This evidence concerns the gene RBM3 and lung cancer.